Clarus Therapeutics Hldgs Analyst Ratings
Clarus Therapeutics Hldgs Analyst Ratings
| Date | Upside/Downside | Analyst Firm | Price Target Change | Rating Change | Previous / Current Rating |
|---|---|---|---|---|---|
| 08/22/2022 | — | Maxim Group | Downgrades | Buy → Hold | |
| 05/17/2022 | 1354.9% | Truist Securities | $7 → $3 | Maintains | Buy |
| 05/17/2022 | 1354.9% | Needham | $8 → $3 | Maintains | Buy |
| 03/31/2022 | 3779.73% | Needham | $12 → $8 | Maintains | Buy |
| 10/13/2021 | 4749.66% | Truist Securities | → $10 | Initiates Coverage On | → Buy |
| 10/06/2021 | 5719.59% | Needham | → $12 | Initiates Coverage On | → Buy |
| 09/29/2021 | 6204.56% | Maxim Group | → $13 | Initiates Coverage On | → Buy |
| 09/20/2021 | 5719.59% | Oppenheimer | → $12 | Initiates Coverage On | → Outperform |
| 09/20/2021 | 9599.32% | Cantor Fitzgerald | → $20 | Initiates Coverage On | → Overweight |
| 日期 | 上行/下行 | 分析公司 | 目標價格變化 | 評級變化 | 上一次/當前評級 |
|---|---|---|---|---|---|
| 08/22/2022 | — | Maxim集團 | 評級下調 | 購買→Hold | |
| 05/17/2022 | 1354.9% | Truist證券 | $7 → $3 | 維護 | 買 |
| 05/17/2022 | 1354.9% | 李約瑟 | $8 → $3 | 維護 | 買 |
| 03/31/2022 | 3779.73% | 李約瑟 | $12 → $8 | 維護 | 買 |
| 10/13/2021 | 4749.66% | Truist證券 | → $10 | 開始承保 | →購買 |
| 10/06/2021 | 5719.59% | 李約瑟 | → $12 | 開始承保 | →購買 |
| 09/29/2021 | 6204.56% | Maxim集團 | → $13 | 開始承保 | →購買 |
| 09/20/2021 | 5719.59% | 奧本海默 | → $12 | 開始承保 | →跑贏大盤 |
| 09/20/2021 | 9599.32% | 康託·菲茨傑拉德 | → $20 | 開始承保 | →超重 |
Clarus Therapeutics Hldgs Questions & Answers
Clarus Treateutics Hldgs問答
The latest price target for Clarus Therapeutics Hldgs (NASDAQ: CRXT) was reported by Maxim Group on August 22, 2022. The analyst firm set a price target for $0.00 expecting CRXT to fall to within 12 months (a possible -100.00% downside). 9 analyst firms have reported ratings in the last year.
Maxim Group於2022年8月22日報道了Clarus Treateutics Hldgs(納斯達克：CRXT)的最新目標價。這家分析公司將目標價定為0.00美元，預計中國鐵通將在12個月內下跌(跌幅可能為-100.00%)。去年有9家分析公司公佈了評級。
The latest analyst rating for Clarus Therapeutics Hldgs (NASDAQ: CRXT) was provided by Maxim Group, and Clarus Therapeutics Hldgs downgraded their hold rating.
MAXIM集團提供了對Clarus Treateutics Hldgs(納斯達克代碼：CRXT)的最新分析師評級，Clarus Treateutics Hldgs下調了其持有評級。
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Clarus Therapeutics Hldgs, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Clarus Therapeutics Hldgs was filed on August 22, 2022 so you should expect the next rating to be made available sometime around August 22, 2023.
分析師在進行了廣泛的研究後得出股票評級，其中包括查閲公共財務報表，與Clarus Treateutics Hldgs的高管和客户交談，以及收聽收益電話會議。大多數分析師每三個月就會這樣做一次，所以你每年應該會得到每家公司每家公司的4個評級。Clarus Treateutics Hldgs的上一次評級是在2022年8月22日提交的，所以你應該預計下一次評級將在2023年8月22日左右提供。
While ratings are subjective and will change, the latest Clarus Therapeutics Hldgs (CRXT) rating was a downgraded with a price target of $0.00 to $0.00. The current price Clarus Therapeutics Hldgs (CRXT) is trading at is $0.21, which is out of the analyst's predicted range.
雖然評級是主觀的，並將發生變化，但最新的Clarus Treateutics Hldgs(CRXT)評級被下調，目標價為0.00美元至0.00美元。Clarus Treateutics Hldgs(CRXT)目前的交易價格為0.21美元，超出了分析師的預測範圍。